| 000 | 01172 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250513194055.0 | ||
| 264 | 0 | _c19991119 | |
| 008 | 199911s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(05)76241-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aElferink, A J | |
| 245 | 0 | 0 |
_aSafety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cOct 1999 |
||
| 300 |
_a1387-8 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Comparative Study; Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticonvulsants _xadverse effects |
| 650 | 0 | 4 |
_aCarbamazepine _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aEpilepsies, Partial _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aVigabatrin _xadverse effects |
| 650 | 0 | 4 |
_aVisual Fields _xdrug effects |
| 700 | 1 | _aToivonen, M | |
| 700 | 1 | _avan Bronswijk, H | |
| 773 | 0 |
_tLancet (London, England) _gvol. 354 _gno. 9187 _gp. 1387-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(05)76241-3 _zAvailable from publisher's website |
| 999 |
_c10490800 _d10490800 |
||